Compounds > gluco-obtusifolin

Page last updated: 2024-12-08

gluco-obtusifolin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

gluco-obtusifolin: isolated from Cassia obtusifolia; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Flora	Rank	Flora Definition	Family	Family Definition
Cassia	genus	A plant genus of the family FABACEAE. Many species of this genus, including the medicinal C. senna and C. angustifolia, have been reclassified into the Senna genus (SENNA PLANT) and some to CHAMAECRISTA.[MeSH]	Fabaceae	The large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID Source	ID
PubMed CID	442761
CHEMBL ID	517625
CHEBI ID	7716
MeSH ID	M0543104

Synonyms (12)

Synonym
obtusifolin 2-glucoside
120163-18-0
C10381 ,
bdbm50133129
CHEMBL517625 ,
chebi:7716 ,
gluco-obtusifolin
AC1L9DD5 ,
8-hydroxy-1-methoxy-3-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyanthracene-9,10-dione
8-hydroxy-1-methoxy-3-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-anthracene-9,10-dione
DTXSID80331940
Q27107567

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
anthraquinone
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
5-hydroxytryptamine receptor 2A	Rattus norvegicus (Norway rat)	IC50 (µMol)	24.3000	0.0004	0.9086	10.0000	AID1256631
Bifunctional epoxide hydrolase 2	Homo sapiens (human)	IC50 (µMol)	24.3000	0.0000	0.5450	9.1000	AID1256631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Process	via Protein(s)	Taxonomy
response to toxic substance	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
positive regulation of gene expression	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
dephosphorylation	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
cholesterol homeostasis	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
stilbene catabolic process	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
phospholipid dephosphorylation	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
regulation of cholesterol metabolic process	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
epoxide metabolic process	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Process	via Protein(s)	Taxonomy
magnesium ion binding	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
epoxide hydrolase activity	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
toxic substance binding	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
phosphatase activity	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
10-hydroxy-9-(phosphonooxy)octadecanoate phosphatase activity	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
lipid phosphatase activity	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
protein homodimerization activity	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
lysophosphatidic acid phosphatase activity	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Process	via Protein(s)	Taxonomy
peroxisome	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
peroxisomal matrix	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
cytosol	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
extracellular exosome	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
peroxisome	Bifunctional epoxide hydrolase 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay ID	Title	Year	Journal	Article
AID1256630	Inhibition of sEH (unknown origin) assessed as 6-methoxy-2-naphthaldehyde formation at 50 uM by fluorometry assay using 40 uM cyano-(6-methoxy-naphthalen-2-yl)-methyl ester as substrate	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Constituents of the seeds of Cassia tora with inhibitory activity on soluble expoxide hydrolease.
AID335922	Antiplatelet activity in rat platelet rich plasma assessed as drug level causing inhibition of arachidonic acid-stimulated platelet aggregation pretreated 2 mins before arachidonic acid challenge
AID1256631	Inhibition of sEH (unknown origin) assessed as 6-methoxy-2-naphthaldehyde formation by fluorometry assay using 40 uM cyano-(6-methoxy-naphthalen-2-yl)-methyl ester as substrate	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Constituents of the seeds of Cassia tora with inhibitory activity on soluble expoxide hydrolease.
AID335924	Antiplatelet activity in rat platelet rich plasma assessed as drug level causing inhibition of collagen-stimulated platelet aggregation pretreated 2 mins before collagen challenge
AID335923	Antiplatelet activity in rat platelet rich plasma assessed as drug level causing inhibition of ADP-stimulated platelet aggregation pretreated 2 mins before ADP challenge
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	13.13 (24.57)
Research Supply Index	1.79 (2.92)
Research Growth Index	4.92 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (13.13)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
emodin Emodin: Purgative anthraquinone found in several plants, especially RHAMNUS PURSHIANA. It was formerly used as a laxative, but is now used mainly as a tool in toxicity studies.. emodin : A trihydroxyanthraquinone that is 9,10-anthraquinone which is substituted by hydroxy groups at positions 1, 3, and 8 and by a methyl group at position 6. It is present in the roots and barks of numerous plants (particularly rhubarb and buckthorn), moulds, and lichens. It is an active ingredient of various Chinese herbs.	2.54	2	trihydroxyanthraquinone	antineoplastic agent; laxative; plant metabolite; tyrosine kinase inhibitor
9,10-anthraquinone 9,10-anthraquinone : An anthraquinone that is anthracene in which positions 9 and 10 have been oxidised to carbonyls.	2.17	1	anthraquinone
chrysophanic acid chrysophanic acid: RN given refers to parent cpd; structure in Merck, 9th ed, #2260. chrysophanol : A trihydroxyanthraquinone that is chrysazin with a methyl substituent at C-3. It has been isolated from Aloe vera and exhibits antiviral and anti-inflammatory activity.	2.54	2	dihydroxyanthraquinone	anti-inflammatory agent; antiviral agent; plant metabolite
physcione physcione: structure. physcion : A dihydroxyanthraquinone that is 9,10-anthraquinone bearing hydroxy substituents at positions 1 and 8, a methoxy group at position 3, and a methyl group at position 6. It has been widely isolated and characterised from both terrestrial and marine sources.	2.54	2	dihydroxyanthraquinone	anti-inflammatory agent; antibacterial agent; antifungal agent; antineoplastic agent; apoptosis inducer; hepatoprotective agent; metabolite
glucose, (beta-d)-isomer beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.	2.78	3	D-glucopyranose	epitope; mouse metabolite
aurantio-obtusin aurantio-obtusin: main anthraquinone in “Jue-Ming-Zi”, therapeutic for hyperlipidemia. aurantio-obtusin : A trihydroxyanthraquinone that is 1,3,7-trihydroxy-9,10-anthraquinone which is by methoxy groups at positions 2 and 8, and by a methyl group at position 6.	2.54	2	trihydroxyanthraquinone
rubrofusarin gentiobioside rubrofusarin gentiobioside: isolated from seeds of Cassia tora; structure in first source	2.11	1
obtusifolin obtusifolin: isolated from Cassia obtusifolia; structure in first source	3.01	4	dihydroxyanthraquinone
scopolamine hydrobromide [no description available]	2.05	1

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.53	2
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.53	2
Allodynia [description not available]	2.1	1
Nerve Pain [description not available]	2.1	1
Neuralgia Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.	2.1	1
Age-Related Memory Disorders [description not available]	2.05	1
Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.	2.05	1

chemdatabank.com